bmiMD review (2026)
bmiMD dispenses via 503A (unnamed). Compounded tirzepatide is from $139/mo (about $179 at maintenance). Semaglutide is from $139/mo (about $169 at maintenance). On our six-pillar rubric it passes some but not all criteria (missing: flat pricing).
Pricing
| Molecule | Advertised | True/mo | 12-mo | Membership | Labs |
|---|---|---|---|---|---|
| Tirzepatide | $139 | $179↑ | $2,148 | — | Incl |
| Semaglutide | $139 | $169↑ | $2,028 | — | Incl |
Dose-increase pricing: +$40 higher doses. Shipping: Free.
Pharmacy & clinical model
Pharmacy disclosure: 503A (unnamed). Medical review: named prescriber / clinician-supervised. Compliance: LegitScript or equivalent disclosed. Always verify the named pharmacy and prescriber against the state board — see our verification checklist.
State availability
bmiMD operates via 503A · free shipping. Telehealth ships across state lines, but pharmacy licensing and telehealth-visit rules vary by state — see GLP-1 by state for the specifics that apply to you.
Pros & cons
Refund & cancellation
Confirm the cancellation policy and whether auto-renew is on by default before enrolling. Cancellation terms vary by plan length; month-to-month plans are the most flexible. (Specific refund terms should be verified on bmiMD's site before publishing.)
Who bmiMD is best for — and who should look elsewhere
Best for: patients who want this provider’s specific program features. Look elsewhere if: you want flat pricing that won’t climb as you titrate up.
bmiMD vs NexLife
| Criterion | bmiMD | NexLife ★ |
|---|---|---|
| Tirzepatide true/mo | $179 | $186 |
| Semaglutide true/mo | $169 | $145 |
| Pricing model | Rises with dose | Flat |
| Pharmacy | 503A (unnamed) | 503A + 503B (named) |
| Passes full rubric | Partial | Yes |
Full NexLife vs bmiMD comparison →
How we evaluated bmiMD
Scored on our six-pillar rubric: true-price transparency, pharmacy traceability, prescriber model, regulatory posture, what's included, and plan terms. Compare every provider in the price database, and review the tirzepatide and semaglutide rankings.
Independent & transparent
This website is independently operated and is not owned by, affiliated with, or paid by any provider listed. We currently earn no commission and accept no payment for placement; all rankings are editorial and based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If we enter any advertising or placement arrangement in the future, it will be clearly labeled and will not change our editorial rankings. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →